Molecularly targeted therapy articles within Nature Reviews Cardiology

Featured

• Review Article | 15 January 2013

  Targeting the renin–angiotensin–aldosterone system in heart failure

  The renin–angiotensin–aldosterone system (RAAS) is well established as a therapeutic target in patients with heart failure. Professors Lang and Struthers discuss new indications for existing drugs—angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and mineralocorticoid-receptor antagonists—as well as novel ways of targeting the RAAS—direct inhibition of renin or dual blockade of the angiotensin II-receptor and neprilysin—in patients who have heart failure with or without reduced ejection fraction.

  • Chim C. Lang
  •  & Allan D. Struthers

• Review Article | 23 October 2012

  Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy

  Ca²⁺ cycling defects in cardiac myocytes are a hallmark of heart failure. Roger Hajjar and colleagues discuss the association between abnormalities in sarcoplasmic reticulum Ca²⁺handling proteins and heart failure as well as the potential therapeutic benefits of novel treatment strategies that target these proteins.

  • Changwon Kho
  • , Ahyoung Lee
  •  & Roger J. Hajjar

• Review Article | 21 February 2012

  Oral factor Xa inhibitors for the long-term management of ACS

  Novel, oral, direct inhibitors of factor Xa are valuable additions to anticoagulation therapy in patients with various thrombotic disorders, but have shown mixed results in trials for secondary prevention in patients with an acute coronary syndrome. Drs Wisler and Becker review the available data, with particular emphasis on the phase III APPRAISE 2 and ATLAS ACS 2–TIMI 51 trials of apixaban and rivaroxaban.

  • James W. Wisler
  •  & Richard C. Becker

• Review Article | 19 July 2011

  Treatment of pulmonary arterial hypertension with targeted therapies

  Pulmonary arterial hypertension (PAH) is a rare, but devastating, disease characterized by progressive obliteration of the pulmonary microvasculature. Over the past decade, an increasing number of therapies targeting the prostacyclin, endothelin, and nitric oxide pathways have been shown to improve the symptoms of PAH and even slow disease progression. O'Callaghan and colleagues review the pharmacological agents currently available for the treatment of PAH and discuss potential novel therapeutic targets in this disease.

  • Dermot S. O'Callaghan
  • , Laurent Savale
  •  & Marc Humbert

• News & Views | 01 March 2011

  Targeting endogenous apo A-I—a new approach for raising HDL

  New therapeutic strategies are needed for patients with atherosclerosis. Despite failing to reach its primary end point, a multicenter, phase II, randomized, placebo-controlled trial of RVX-208—an oral, synthetic quinazoline molecule that stimulates expression of endogenous apolipoprotein A-I—has provided somewhat encouraging results. Nevertheless, detailed investigations are still needed if we are ever to realize the full atheroprotective potential of novel HDL-targeted therapies.

  • Prediman K. Shah

• Review Article | 22 June 2010

  Novel therapeutic targets for hypertension

  Although effective therapies for hypertension exist, the prevalence of elevated blood pressure and resistant hypertension is increasing and novel treatment strategies are needed. In this Review, Drs. Paulis and Unger discuss new targets for antihypertensive therapy, many of which, including renalase and the (pro)renin receptor, are based on modulation of the renin–angiotensin–aldosterone system. Invasive strategies, such as renal denervation, are also explored.

  • Ludovit Paulis
  •  & Thomas Unger

• Research Highlight | 01 January 2010

  Targeting collagen metabolism in preserved systolic function HF

  • Alexandra King